HCC70細(xì)胞 
	
		器官來(lái)源:	**
	
	
		運(yùn)輸方式:	凍存運(yùn)輸
	
	
		組織來(lái)源:	duct
	
	
		生長(zhǎng)狀態(tài):	貼壁生長(zhǎng)
	
	
		數(shù)量:	大量
	
	
		年限:	TNM stage IIIA, grade 3
	
	
		ATCC Number:	CRL-2315?
	
	
		相關(guān)**:	導(dǎo)管癌
	
	
		細(xì)胞形態(tài):	上皮樣
	
	
		是否是腫瘤細(xì)胞:	1
	
	
		物種來(lái)源:	人
	
	
		HCC70細(xì)胞Designations:	HCC70
	
	
		Depositors:	 AF Gazdar, AK Virmani
	
	
		Biosafety Level:	1
	
	
		Shipped:	frozen
	
	
		Medium & Serum:	See Propagation
	
	
		Growth Properties:	adherent, The line grows as attached medium-sized epithelial cells without floating cells.
	
	
		Organism:	Homo sapiens
	
	
		Morphology:	epithelial
	
	
		
	
	
		Source:	Organ: mammary gland; breast
	
	
		Tissue: duct
	
	
		Tumor Stage: TNM stage IIIA, grade 3
	
	
		Disease: primary ductal carcinoma
	
	
		Cellular Products:	Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
	
	
		Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. HCC70細(xì)胞Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
	
	
		Restrictions:	The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
	
	
		Applications:	HCC70 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
	
	
		However, recent studies performed outside of ATCC have given conflicting results about the status of the estrogen receptor for these cells.
	
	
		The cells are poorly differentiated.
	
	
		The cells overexpress p53, and are negative for the expression of Her2-neu oncogenes.
	
	
		The depositor of CRL-2315 initially reported the cells were positive for estrogen receptors.
	
	
		Receptors:	progesterone receptor, not expressed
	
	
		Oncogene:	her2/neu -, p53 + (overexpressed)
	
	
		DNA Profile (STR):	Amelogenin:X
	
	
		CSF1PO:10,14
	
	
		HCC70細(xì)胞D13S317:12
	
	
		D16S539:9,13
	
	
		D5S818:12,13
	
	
		D7S820:10,11
	
	
		THO1:9
	
	
		TPOX:10
	
	
		vWA: 13,15
	
	
		Cytogenetic Analysis:	polyploid
	
	
		Age:	49 years
	
	
		Gender:	female
	
	
		Ethnicity:	Black
	
	
		Comments:	The HCC70 cell line was initiated from a primary ductal carcinoma on June 3, 1992, and took 44 months to establish.
	
	
		The cells are poorly differentiated.
	
	
		The tumor was classified as TNM Stage IIIA, grade 3, invasive ductal carcinoma with metastases in 4 out of 17 lymph nodes.
	
	
		The cells overexpress p53, and are negative for the expression of Her2-neu oncogenes.
	
	
		HCC70 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
	
	
		The depositor of CRL-2315 initially reported the cells were positive for estrogen receptors. However, recent studies performed outside of ATCC have given conflicting results about the status of the estrogen receptor for these cells. An independent study, by ATCC Scientists, is underway to assess the estrogen receptor status; results of this study will be published online upon completion.
	
	
		Propagation: HCC70細(xì)胞ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
	
	
		Atmosphere: air, 95%; carbon dioxide (CO2), 5%
	
	
		Temperature: 37.0°C
	
	
		Subculturing:	Protocol:
	
	
		Remove and discard culture medium.
	
	
		Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
	
	
		Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
	
	
		Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.
	
	
		Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
	
	
		Add appropriate aliquots of the cell suspension to new culture vessels.
	
	
		Incubate cultures at 37?C.
	
	
		
	
	
		Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
	
	
		Medium Renewal: Every 2 to 3 days
	
	
		Preservation:	Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
	
	
		Storage temperature: liquid nitrogen vapor phase
	
	
		Related Products:	Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
	
	
		recommended serum:ATCC 30-2020
	
	
		References:	38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. HCC70細(xì)胞PubMed: 9833771
	
	
		16173688: Kao J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PlosONE 4 (7): e 6146, 2009
	
	
		16173689: Kim MS, et al. Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform. PlosONE 5 (5): e10441, 2010